Clinical trials: Malaria
Malaria
Trial to Evaluate L9LS in Healthy Adults
Background: Malaria is a parasitic disease carried by mosquitoes in tropical areas. There is no vaccine to prevent malaria infection. If not treated right away, it can become serious or deadly.
- Trial name
- VRC 614 (NCT05019729)
- Testing
- VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria,Falciparum
Safety and Efficacy of R0.6C Vaccine
This is a first-in-human phase I, open-label, single-site, dose escalation study to determine the safety, tolerability and Plasmodium falciparum transmission reducing activity of the R0.6C vaccine in two different adjuvant…
- Trial name
- STOP-TRANS (NCT04862416)
- Testing
- R0.6C transmission blocking vaccine
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria, Vivax
Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1
This is an Open label, first-in-human, Phase I/IIa, blood-stage P. vivax malaria vaccine trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1…
- Trial name
- NCT04201431
- Testing
- PvDBPII/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Vivax
VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines
This is an open label, Phase IIa, controlled human malaria infection (CHMI) study aimed to assess whether the new vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP can protect against malaria infection.
- Trial name
- NCT04009096
- Testing
- ChAd63 PvDBP and MVA PvDBP
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults
MALARIA-092 (NCT03162614) study was designed to evaluate the efficacy, immunogenicity and safety of various dose schedules and formulations of GSK Biologicals' candidate malaria vaccine (RTS,S/AS01E) in healthy malaria-naïve…
- Trial name
- NCT03824236
- Testing
- RTS,S/AS01E (SB257049)
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Stimulating Private Sector Malaria Control
Preliminary evidence from ongoing research provides strong indications that protecting farmers from malaria would be profitable for outgrowing agribusinesses in sub-Saharan Africa.
- Trial name
- Outgrowers (NCT01397851)
- Testing
- Insecticide-treated net (BASF Incerceptor)
- Where
- Zambia
- Volunteers
- 81,597 people, healthy volunteers welcome
- Sponsor
- PATH
Healthy
First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
The primary purpose of this study was to investigate the safety and tolerability of M5717 and to characterize the Pharmacokinetics (PK) /Pharmacodynamic relationship between M5717 PK and parasite clearance in healthy participants…
- Trial name
- NCT03261401
- Testing
- M5717
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Plasmodium Falciparum
Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.
The candidate malaria vaccine RTS,S/AS02A developed by GSK Biologicals demonstrated 30% efficacy against clinical episodes of malaria and approximately 58% efficacy against severe malaria disease.
- Trial name
- NCT00197054
- Testing
- RTS, S/AS01B, RTS, S/AS02A, Rabipur (Rabies) Vaccine
- Where
- Kenya
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine
The RTS,S/AS02A vaccine (or GSK 257049 vaccine), GSK Biologicals' candidate Plasmodium falciparum (P. falciparum) malaria vaccine is being developed for the routine immunization of infants and children living in malaria endemic…
- Trial name
- NCT00323622
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Engerix™-B, Hiberix®
- Where
- Mozambique
- Volunteers
- 1,737 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Drug-Drug Interaction, HIV Infection
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG)-based antiretroviral therapy (ART)…
- Trial name
- DPART (NCT04487145)
- Testing
- Dihydroartemisinin-piperaquine
- Where
- 2 sites in Uganda
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
This is a single-centre, controlled, open label study using P. falciparum-induced blood stage malaria (IBSM) infection to assess the effectiveness of OZ439 as a gametocytocidal agent, as well as its treatment effects on…
- Trial name
- OZGAM (NCT02431650)
- Testing
- OZ439, Primaquine
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Trial to Evaluate CIS43LS in Healthy Adults
Background: People get malaria when they are bitten by an infected mosquito. Malaria can be serious and sometimes deadly. Although there are medicines to treat malaria, there is no vaccine that fully prevents infection.
- Trial name
- NCT04206332
- Testing
- VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Plasmodium Vivax
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
This is a first-in-humans safety, immunogenicity and efficacy study with recombinant protein VMP001, a Plasmodium vivax circumsporozoite (CS) protein based vaccine.
- Trial name
- NCT01157897
- Testing
- VMP001, P. vivax sporozoite challenge
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
This is a study in which healthy adult volunteers will be given either an experimental Malaria vaccine or a saline control vaccine. Each volunteer will receive three vaccinations in total.
- Trial name
- NCT02925403
- Testing
- R21/Matrix-M1, Saline
- Where
- Burkina Faso
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Gut and Azithromycin Mechanisms in Infants and Children II
Childhood mortality is decreasing worldwide. However, many sub-Saharan countries still have high children under 5 mortality rates.
- Trial name
- GAMINII (NCT04315272)
- Testing
- Azithromycin
- Where
- Burkina Faso
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet
The primary objective of this study is to determine the bioequivalence of the combination of pyronaridine and artesunate (180:60mg) to-be-marketed tablet to the clinical trial reference tablet administered as a single total dose…
- Trial name
- NCT00682630
- Testing
- pyronaridine artesunate clinical trial reference tablets, pyronaridine artesunate to-be-marketed tablets
- Where
- Switzerland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Plasmodium Falciparum
Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe
This is an open label, human pilot study to optimise controlled human malaria infection (CHMI) administered by Plasmodium falciparum sporozoites (PfSPZ. Volunteers will be inoculated with PfSPZ Challenge.
- Trial name
- NCT01465048
- Testing
- Plasmodium falciparum sporozoites 2sites, Plasmodium falciparum sporozoites 1 site, Plasmodium falciparum sporozoites 1site
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil
Background: The World Health Organization recommends that antimalarial treatment policies be evaluated every few years to check their efficacy. P.
- Trial name
- NCT02043652
- Testing
- Chloroquine, Primaquine
- Where
- Brazil
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Malaria, Falciparum
Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine
This trial is currently evaluating one candidate malaria vaccine, FMP1/AS02A. This candidate malaria vaccine is being developed for the routine immunization of infants and children living in malaria-endemic areas.
- Trial name
- NCT00223990
- Testing
- FMP1/AS02A, RabAvert
- Where
- Kenya
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate
The primary objective of the drug-drug interaction study is to evaluate any drug interaction between the CYP2D6 substrate metoprolol and pyronaridine-artesunate in healthy volunteers.
- Trial name
- NCT01523002
- Testing
- Metoprolol and pyronaridine-artesunate, pyronaridine-artesunate
- Where
- Switzerland
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture